128 related articles for article (PubMed ID: 1745969)
21. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.
De León DD; Lange BJ; Walterhouse D; Moshang T
J Clin Endocrinol Metab; 2002 Oct; 87(10):4452-6. PubMed ID: 12364417
[TBL] [Abstract][Full Text] [Related]
22. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
23. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
[TBL] [Abstract][Full Text] [Related]
24. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
25. [Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP'DDD alone].
Remond S; Bardet S; Charbonnel B
Presse Med; 1992 May; 21(18):865. PubMed ID: 1535153
[No Abstract] [Full Text] [Related]
26. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
27. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature.
Wooten MD; King DK
Cancer; 1993 Dec; 72(11):3145-55. PubMed ID: 8242539
[TBL] [Abstract][Full Text] [Related]
28. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.
Vassilopoulou-Sellin R; Guinee VF; Klein MJ; Taylor SH; Hess KR; Schultz PN; Samaan NA
Cancer; 1993 May; 71(10):3119-23. PubMed ID: 8490842
[TBL] [Abstract][Full Text] [Related]
29. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
30. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.
Berruti A; Terzolo M; Paccotti P; Veglio F; Pia A; Dogliotti L; Angeli A
Tumori; 1992 Oct; 78(5):345-8. PubMed ID: 1494808
[TBL] [Abstract][Full Text] [Related]
31. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
32. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
33. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms.
Kintzer PP; Peterson ME
J Am Vet Med Assoc; 1994 Jul; 205(1):54-61. PubMed ID: 7928549
[TBL] [Abstract][Full Text] [Related]
34. Prolonged bleeding time due to mitotane therapy.
Haak HR; Caekebeke-Peerlinck KM; van Seters AP; Briët E
Eur J Cancer; 1991; 27(5):638-41. PubMed ID: 1828976
[TBL] [Abstract][Full Text] [Related]
35. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
36. Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma.
Hague RV; May W; Cullen DR
Clin Endocrinol (Oxf); 1989 Jul; 31(1):51-7. PubMed ID: 2574647
[TBL] [Abstract][Full Text] [Related]
37. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.
Schteingart DE; Sinsheimer JE; Counsell RE; Abrams GD; McClellan N; Djanegara T; Hines J; Ruangwises N; Benitez R; Wotring LL
Cancer Chemother Pharmacol; 1993; 31(6):459-66. PubMed ID: 8453685
[TBL] [Abstract][Full Text] [Related]
39. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Demeure MJ; Somberg LB
Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
[TBL] [Abstract][Full Text] [Related]
40. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
